Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 246

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

Open access
Yu, Helena A., Goto, Yasushi, Hayashi, Hidetoshi, Felip, Enriqueta, Chih-Hsin Yang, James, Reck, Martin, Yoh, Kiyotaka, Lee, Se-Hoon, Paz-Ares, Luis, Besse, Benjamin, Bironzo, Paolo, Kim, Dong-Wan, Johnson, Melissa L., Wu, Yi-Long, John, Thomas, Kao, Steven, Kozuki, Toshiyuki, Massarelli, Erminia, Patel, Jyoti, Smit, Egbert, Reckamp, Karen L., Dong, Qian, Shrestha, Pomy, Fan, Pang-Dian, Patel, Parul, Sporchia, Andrea, Sternberg, David W., Sellami, Dalila, Jänne, Pasi A. · 2023 · Journal of Clinical Oncology

Abstract

PURPOSE: Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. We assessed the efficacy and safety of HER3-DXd in patients with epidermal growth factor receptor ( EGFR)–mutated non–small-cell lung cancer (NSCLC). METHODS: This phase II study (ClinicalTrials.gov identifier: NCT04619004 ) was designed to evaluate HER3-DXd in patients with advanced EGFR-mutated NSCLC previously treated with EGFR tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy (PBC). Patients received HER3-DXd 5.6 mg/kg intravenously once every 3 weeks or an uptitration regimen (3.2 → 4.8 → 6.4 mg/kg). The primary end point was confirmed objective response rate (ORR; RECIST 1.1) by blinded independent central review (BICR), with a null hypothesis of 26.4% on the basis of historical data. RESULTS: Enrollment into the uptitration arm closed early on the basis of a prespecified benefit-risk assessment of data from the phase I U31402-A-U102 trial. In total, 225 patients received HER3-DXd 5.6 mg/kg once every 3 weeks. As of May 18, 2023, median study duration was 18.9 (range, 14.9-27.5) months. Confirmed ORR by BICR was 29.8% (95% CI, 23.9 to 36.2); median duration of response, 6.4 months; median progression-free survival, 5.5 months; and median overall survival, 11.9 months. The subgroup of patients with previous osimertinib and PBC had similar outcomes. Efficacy was observed across a broad range of pretreatment tumor HER3 membrane expression levels and across diverse mechanisms of EGFR TKI resistance. In patients with nonirradiated brain metastases at baseline (n = 30), the confirmed CNS ORR by BICR per CNS RECIST was 33.3% (95% CI, 17.3 to 52.8). The safety profile (National Cancer Institute Common Terminology Criteria for Adverse Events v5.0) was manageable and tolerable, consistent with previous observations. CONCLUSION: After tumor progression with EGFR TKI therapy and PBC in patients with EGFR-mutated NSCLC, HER3-DXd once every 3 weeks demonstrated clinically meaningful efficacy with durable responses, including in CNS metastases. A phase III trial in EGFR-mutated NSCLC after progression on an EGFR TKI is ongoing (HERTHENA-Lung02; ClinicalTrials.gov identifier: NCT05338970 ).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.23.01476

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 246

Metadata

Authors
Yu, H. A., Goto, Y., Hayashi, H., Felip, E., Chih-Hsin Yang, J., Reck, M., Yoh, K., Lee, S.-H., Paz-Ares, L., Besse, B., Bironzo, P., Kim, D.-W., Johnson, M. L., Wu, Y.-L., John, T., Kao, S., Kozuki, T., Massarelli, E., Patel, J., Smit, E., Reckamp, K. L., Dong, Q., Shrestha, P., Fan, P.-D., Patel, P., Sporchia, A., Sternberg, D. W., Sellami, D., & Jänne, P. A.
Venue
Journal of Clinical Oncology
Published
2023-12-10
Volume
41
Issue
35
Pages
5363-5375
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4386582468
Cited by
246
References
5
FWCI
38.76
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. https://app.cochat.ai/papers/10.1200/jco.23.01476
The paper
Yu, H. A., Goto, Y., Hayashi, H., Felip, E., Chih-Hsin Yang, J., Reck, M., Yoh, K., Lee, S.-H., Paz-Ares, L., Besse, B., Bironzo, P., Kim, D.-W., Johnson, M. L., Wu, Y.-L., John, T., Kao, S., Kozuki, T., Massarelli, E., Patel, J., . . . Jänne, P. A. (2023). HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01476

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.